<SEC-DOCUMENT>0001493152-24-011614.txt : 20240328
<SEC-HEADER>0001493152-24-011614.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240328080518
ACCESSION NUMBER:		0001493152-24-011614
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240328
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Imunon, Inc.
		CENTRAL INDEX KEY:			0000749647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				521256615
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15911
		FILM NUMBER:		24793628

	BUSINESS ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648
		BUSINESS PHONE:		(609) 896-9100

	MAIL ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celsion CORP
		DATE OF NAME CHANGE:	20071121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CELSION CORP
		DATE OF NAME CHANGE:	19980515

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEUNG LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:IMNN="http://imunon.com/20240328">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_IMNN_imunon.com_20240328 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240328_20240328 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0000749647 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:AmendmentFlag" id="ixv-401">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityCentralIndexKey" id="ixv-402">0000749647</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imnn-20240328.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-03-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-28</xbrli:startDate>
        <xbrli:endDate>2024-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20240328__20240328_z0zJq6ZT0d71"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:DocumentType" id="ixv-422">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20240328__20240328_z8g2grrX1979"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-423">March 28, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20240328__20240328_zlIKXYoB5g1g"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityRegistrantName" id="ixv-424">Imunon,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240328__20240328_zKnLlTZLtzw2"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-425">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20240328__20240328_zQtww5nJNPXe"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityFileNumber" id="ixv-426">001-15911</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20240328__20240328_zx3BuCWJjc0i"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityTaxIdentificationNumber" id="ixv-427">52-1256615</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20240328__20240328_zLm0wAwT7RPc"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityAddressAddressLine1" id="ixv-428">997
    Lenox Drive</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20240328__20240328_z4zjoRsiOxUh"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityAddressAddressLine2" id="ixv-429">Suite 100</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressCityOrTown_c20240328__20240328_zOmGQZqkADq6"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityAddressCityOrTown" id="ixv-430">Lawrenceville</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240328__20240328_zJq5LsHCGu22"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityAddressStateOrProvince" id="ixv-431">NJ</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20240328__20240328_zq3OfOL0kGp9"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:EntityAddressPostalZipCode" id="ixv-432">08648-2311</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal
    executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--CityAreaCode_c20240328__20240328_z9dH11hliyyj"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:CityAreaCode" id="ixv-433">(609)</ix:nonNumeric></span>
<span id="xdx_90A_edei--LocalPhoneNumber_c20240328__20240328_zvZ95RQDTDij"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:LocalPhoneNumber" id="ixv-434">896-9100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20240328__20240328_zhAup7VBBNyj"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-435">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20240328__20240328_zFGYUFkLQfOk"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-436">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20240328__20240328_zng1FnJV77M1"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="ixv-437">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20240328__20240328_zCciMO1Zoba9"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-438">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20240328__20240328_z8FaShJdwpPg"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:Security12bTitle" id="ixv-439">Common stock, par value
    $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20240328__20240328_zxd58d68EuO5"><ix:nonNumeric contextRef="AsOf2024-03-28" name="dei:TradingSymbol" id="ixv-440">IMNN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_904_edei--SecurityExchangeName_c20240328__20240328_zelua1NH9lp5"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-441">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20240328__20240328_zpVXWS341zG"><ix:nonNumeric contextRef="AsOf2024-03-28" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-442">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2023. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>On
March 21, 2024, Imunon, Inc. announced it would hold a conference call on March 28, 2024 to discuss its financial results for the year
ended December 31, 2023 and provide a business update. The conference call will also be broadcast live on the internet at <span style="text-decoration: underline">http://www.imunon.com</span>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this report, including the exhibit hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with
the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these
forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.6in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release titled &#8220;Imunon Reports 2023 Financial Results and Provides Business Update&#8221; issued by Imunon, Inc. on March 28, 2024</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMUNON
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 28, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Jeffrey
    W. Church</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Church</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMUNON
Reports 2023 Financial Results and Provides Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conference
Call Begins Today at 10:00 a.m. Eastern Time</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LAWRENCEVILLE,
N.J. (March 28, 2024) &ndash; IMUNON, Inc. (NASDAQ: IMNN)</B>, <FONT STYLE="background-color: white">a clinical-stage drug-development
company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, </FONT>today reported financial results
for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based
interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian
cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for
the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Highlights
of 2023 and recent weeks include the following:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported
                                            interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in the
                                            Phase 2 OVATION 2 Study in patients with advanced ovarian cancer. Interim data from the intent-to-treat
                                            (ITT) population showed an approximate 30% delay in disease progression or death in the treatment
                                            arm compared with the control arm, and preliminary OS data showed an approximate nine-month
                                            improvement in the treatment arm over the control arm.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrolled
                                            four patients in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab
                                            in patients with advanced ovarian cancer at the University of Texas MD Anderson Cancer Center,
                                            and recently added Memorial Sloan Kettering Cancer Center as a clinical site for this study.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announced
                                            results from a non-human primate study confirming PlaCCine as a viable modality for the development
                                            of the next generation of prophylactic vaccines.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reported
                                            pre-clinical data demonstrating PlaCCine vaccines elicit robust and more durable T cell responses
                                            than commercial mRNA vaccines in animal models, signaling that PlaCCine vaccines may provide
                                            greater protection against reinfection, hospitalization or death.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submitted
                                            an Investigational New Drug (IND) application with the U.S. Food and Drug Administration
                                            (FDA) in the first quarter of 2024 for a Phase 1/2 proof-of-concept clinical trial with a
                                            seasonal COVID-19 booster vaccine.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Launched
                                            a new current Good Manufacturing Practices production facility to efficiently support R&amp;D
                                            with significantly lower costs for infectious disease  vaccines, and DNA-based immuno-oncology
                                            therapies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IMUNON
has a dedicated management team to advance our two platform technologies and execute our strategic plan,&rdquo; said Mr. Michael
Tardugno, IMUNON&rsquo;S Executive Chairman. &ldquo;We remain on track to report topline results mid-year from the OVATION 2 Study
with IMNN-001 in advanced ovarian cancer. If the interim data are confirmed in the final readout, the observed PFS benefit would represent
a clinically meaningful outcome. We also remain on track to begin a Phase 1 proof-of-concept clinical study in the second quarter of
2024 with a seasonal COVID-19 booster vaccine, following FDA clearance of our IND application. Our objective is to confirm the safety
and immunogenicity of our clinical vaccine in humans. Based on these results, we will advance discussions with potential partners to
continue development of the platform.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IMUNON
made significant progress during 2023, in particular with advancing our clinical programs in immuno-oncology with IMNN-001, our gene-mediated
IL-12 immunotherapy. In September we reported interim PFS and OS data in our OVATION 2 Study suggesting a delay in disease progression
or death in the treatment arm of approximately 30% compared with the control arm, with the hazard ratio nearing the study objective.
Preliminary OS data followed a similar trend, showing an approximate nine-month improvement in the treatment arm over the control arm.
Subgroup analyses suggest patients treated with a PARPi as maintenance therapy had longer PFS and OS if they were also treated with IMNN-001,
compared with patients treated with neoadjuvant chemotherapy (NACT) only,&rdquo; he added.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PlaCCine modality continues to advance with very encouraging data. We demonstrated the validity of this proprietary technology in prophylactic
vaccines, with impressive preclinical proof-of-concept data not only in COVID-19, but also in a multiple of other pathogenic viruses.
We also completed the evaluation of our vaccines in non-human primates. The final data from these studies show excellent immunological
response and viral clearance. In a recent mouse study, we demonstrated that a single dose of our PlaCCine vaccine without a booster dose
produced longer duration of IgG responses and higher T cell activation than an mRNA vaccine. We have also demonstrated continued drug
stability at standard refrigerated temperature of 4&deg;C for more than 12 months, representing a significant commercial advantage over
commercial mRNA-based vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the high costs and long lead times of third party CMOs, we have strategically invested in, and completed development of in-house pilot
manufacturing capabilities for DNA plasmids and synthetic delivery systems. Our scientists can now select any protein from the human
or pathogen proteomes to be engineered. Our labs also can conduct testing and run experiments in a variety of animal disease models independently
supporting bench-to-bedside development of our novel therapies and vaccines. These capabilities are expected to allow us to realize our
goal of attracting strategic partners while minimizing dependence on vendors so that we control both the costs and the development timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited about the key value-creating milestones we face in 2024. The potential for advances in treating late-stage ovarian cancer
may be within reach, while a better vaccine platform technology holds tremendous commercial promise. We look forward to continuing to
create value for our stockholders and for patients,&rdquo; Mr. Tardugno concluded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECENT
DEVELOPMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>IMNN-001
Immunotherapy</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Reported
Interim PFS and OS Data in OVATION 2 Study in Advanced Ovarian Cancer. </B>In September 2023, the Company</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced
interim PFS and OS data with IMNN-001 in its OVATION 2 Study. This study is evaluating the dosing, safety, efficacy and biological activity
of intraperitoneal IMNN-001 in combination with NACT in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or
primary peritoneal cancer. NACT is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles
of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to
treat any residual tumor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
open-label study is directional and designed with an 80% confidence interval to show an approximate 33% improvement in PFS, when comparing
the treatment arm (NACT + IMNN-001) with the control arm (NACT only). The secondary endpoints include OS, objective response rate, pathological
response, surgical response and serologic response. The final readout of this study is expected in mid-2024. A positive readout would
inform next development steps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
                                            data from the ITT population showed efficacy trends in PFS, demonstrating a delay in disease
                                            progression in the treatment arm of approximately three months compared with the control
                                            arm, with the hazard ratio nearing the study objective. Preliminary OS data followed a similar
                                            trend, showing an approximate nine-month improvement in the treatment arm over the control
                                            arm.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-prespecified
                                            subgroup analyses suggest that patients treated with a PARPi as maintenance therapy had longer
                                            PFS and OS if they were also treated with IMNN-001, compared with patients treated with NACT
                                            only.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            median PFS in the PARPi + NACT group and the PARPi + NACT + IMNN-001 group was 15.7 months
                                            and 23.7 months, respectively.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            median OS in the PARPi + NACT group was 45.6 months and has not yet been reached in the PARPi
                                            + NACT + IMNN-001 group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
benefits were seen in other secondary endpoints including an approximately 25% higher R0 tumor resection score and a doubling of the
CRS 3 chemotherapy response score to approximately 30% in the treatment arm, versus 14% in the control arm. A complete tumor resection
(R0) is a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Chemotherapy response
score is considered a good prognostic indicator in ovarian cancer. Safety analyses continue to show good tolerability of IMNN-001 in
this setting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Began
Treatment in a Phase 1/2 Clinical Trial Evaluating IMNN-001 in Combination with Bevacizumab (Avastin&reg;) in Advanced Ovarian Cancer.
</B>In October 2023, the first patient was enrolled in this trial at the University of Texas MD Anderson Cancer Center. This trial is
expected to enroll 50 patients with Stage III/IV ovarian cancer. Patients undergoing frontline neoadjuvant therapy will be randomized
1:1 to receive standard chemotherapy plus bevacizumab, or standard chemotherapy plus bevacizumab and IMNN-001. The trial&rsquo;s primary
endpoint is detection of minimal residual disease (MRD) by second-look laparoscopy and the secondary endpoint is PFS. This trial will
also include a wealth of translational endpoints aimed at understanding the clonal evolution and immunogenomic features of the MRD phase
of ovarian cancer that is currently undetectable by imaging or tumor markers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, the Company announced that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients
in this clinical trial. A total of four patients have been enrolled in the study to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PlaCCine:
Developing the Prophylactic Vaccines of the Future</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Preclinical
Data for IMUNON&rsquo;s PlaCCine DNA-Based Vaccine in SARS-CoV-2 Published in Peer-Reviewed Journal <I>Vaccine</I>. </B>In February 2024,
the Company </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced that an article titled &ldquo;Strong
immunogenicity &amp; protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functionalized polymer&rdquo; was published
in the peer-reviewed journal <I>Vaccine, </I>by Elsevier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
article is available at <U>https://authors.elsevier.com/sd/article/S0264-410X(24)00077-X</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study described in the article used IMUNON&rsquo;s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both
alone and in combination. Data from the study show:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON&rsquo;s
                                            proprietary formulation of functionalized polymer protected DNA from degradation and enhanced
                                            protein expression, while the combination with an adjuvant led to an increase in immunogenicity.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PlaCCine
                                            vaccines are stable for up to one year at 4&deg;C and at least one month at 37&deg;C.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaccination
                                            with PlaCCine resulted in the induction of spike-specific neutralizing antibodies and cytotoxic
                                            T cells.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the <I>in vivo</I> challenge model, the vaccine-induced immune response was capable of suppressing
                                            viral replication.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
                                            inserts can be cloned into the PlaCCine backbone (a plug-and-play strategy), therefore allowing
                                            for an immune response with broader protection.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>IMUNON&rsquo;s
Vice President</B></FONT><B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of R&amp;D Presented at the Vaccines
Summit-2023</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In November 2023, Jean Boyer, Ph.D.
delivered a presentation titled &ldquo;Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized
Polymeric Delivery System&rdquo; during the &ldquo;New Vaccine Development&rdquo; session at the Vaccines Summit-2023 in Boston. The
presentation included updated data related to IMUNON&rsquo;s PlaCCine SARS-CoV-2 DNA vaccine, including studies showing PlaCCine expresses
spike proteins in mice and primates demonstrating induction of spike-specific neutralizing antibody responses and CD8 and CD4 spike-specific
cellular responses. The induced immune responses in vaccinated mice were maintained for up to 14 months after vaccination. The presentation
also showed that in both primates and mice, the induced immune responses reduced lung viral loads by more than 90%. In mouse studies,
robust immune responses were observed following a single intramuscular injection of either PlaCCine SARS-CoV-2 DNA vaccine or a novel
PlaCCine Lassa Virus DNA vaccine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>IMUNON&rsquo;s
Chief Science Officer Presented at the 3<SUP>rd</SUP> International Vaccines Congress.</B> In October 2023, Khursheed Anwer, Ph.D. delivered
a presentation titled &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A DNA-based Vaccine Technology
Independent of Virus or Device&rdquo; at the 3<SUP>rd</SUP> International Vaccines Congress in Boston. The presentation described the
multiple advantages of the PlaCCine modality over current commercial vaccine platforms. The presentation also described the versatility
of the PlaCCine modality, demonstrating activity against Marburg and influenza viruses in collaboration with the Wistar Institute, and
activity against Lassa virus being evaluated at the NIH/NIAID.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><U>Corporate
Developments</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Received
$1.3 Million in Non-Dilutive Funding from the Sale of New Jersey Net Operating Losses.</B> In March 2024, the Company received $1.3 million
in net cash proceeds from the sale of approximately $1.4 million of its unused New Jersey net operating losses (NOLs). The NOL sales
cover the tax year 2022 and are administered through the New Jersey Economic Development Authority&rsquo;s Technology Business Tax Certificate
Transfer (NOL) program. This non-dilutive funding further strengthened the Company&rsquo;s balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Results for the Year Ended December 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON
reported a net loss for 2023 of $19.5 million, or $2.16 per share, compared with a net loss for 2022 of $35.9 million, or $5.03 per share.
Operating expenses were $21.0 million for 2023, a decrease of $4.4 million or 17% from $25.4 million for 2022. The Company recognized
tax benefits from the sale of its New Jersey NOLs of $1.3 million and $1.6 million in 2023 and 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development (R&amp;D) expenses were $11.3 million for 2023, a decrease of $0.4 million from $11.7 million for 2022. Costs associated
with the OVATION 2 Study were $1.2 million and $1.5 million for 2023 and 2022, respectively. Costs associated with the Phase 3 OPTIMA
Study were de minimis for 2023 compared with $1.0 million for 2022. Other clinical and regulatory costs were $1.8 million for 2023 compared
with $1.9 million for 2022. R&amp;D costs associated with the development of IMNN-001 to support the OVATION 2 Study, as well as development
of the PlaCCine DNA vaccine technology platform, were $6.0 million for 2023 compared with $6.1 million for 2022. CMC costs increased
to $2.3 million for 2023 compared with $1.2 million for 2022 due to the development of in-house pilot manufacturing capabilities for
DNA plasmids and nanoparticle delivery systems in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $9.7 million for 2023 compared with $13.7 million for 2022. This decrease was primarily attributable
to lower non-cash stock compensation expense ($1.3 million), lower employee-related costs ($0.8 million), lower legal costs ($1.0 million),
lower insurance costs ($0.6 million) and lower public company expenses ($0.2 million), offset by higher consulting fees ($0.2 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
non-operating income was $0.2 million for 2023 compared with other non-operating expenses of $12.5 million for 2022. This increase was
attributable to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
                                            income from the Company&rsquo;s short-term investments was $1.2 million for 2023 and $0.5
                                            million for 2022.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            June 2021, the Company entered into a $10.0 million loan facility with Silicon Valley Bank
                                            (SVB). The Company immediately used $6.0 million from this facility to retire all outstanding
                                            indebtedness with Horizon Technology Finance Corporation. In connection with the loan facility,
                                            the Company incurred $0.2 million in interest expense in 2023 compared with $0.5 million
                                            in 2022. In the second quarter of 2023, the Company terminated the SVB Loan Facility, paid
                                            early termination and end-of-term charges and recognized $0.3 million as a loss on debt extinguishment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            2022, the Company recognized (i) an impairment charge of $13.4 million due to the write off
                                            of In-Process Research &amp; Development (IPR&amp;D) assets and (ii) a non-cash gain of $5.4
                                            million due to the write-off of the earnout milestone liability because of the requirements
                                            not being achieved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            2022, the Company incurred additional interest expense attributable to the one-time payment
                                            of $4.5 million in interest and offering expenses resulting from the sale and subsequent
                                            redemption of $28.5 million of Series A &amp; B convertible redeemable preferred stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used for operating activities was $19.0 million for 2023 compared with $23.1 million for 2022. This decrease was primarily due to
the one-time payment of $4.5 million in interest expense resulting from the sale and subsequent redemption of $28.5 million of Series
A &amp; B convertible redeemable preferred stock in the first quarter of 2022. Cash used in financing activities was $3.6 million for
2023 from the pay-off of the SVB loan ($6.4 million), offset by sales under the Company&rsquo;s At-the-Market Equity Facility ($2.8 million).
This compares with cash provided by financing activities of $6.7 million for 2022 resulting from an at-the-market equity offering ($6.2
million) and sales under the Company&rsquo;s At-the-Market Equity Facility ($0.5 million).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company ended 2023 with </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15.7 million <FONT STYLE="background-color: white">in
cash, investments and accrued interest receivable. Along with future planned sales of the Company&rsquo;s remaining $1.3 million of New
Jersey NOLs, the Company believes it has sufficient capital resources to fund its operations into the fourth quarter of 2024.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conference
Call and Webcast</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m.
Eastern time today. To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll)
and ask for the IMUNON 2023 Earnings Call. A live webcast of the call will be available <U>here</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
call will be archived for replay until April 11, 2024. The replay can be accessed at 877-344-7529 (U.S. Toll-Free), 855-669-9658 (Canada
Toll-Free) or 412-317-0088 (International Toll), using the replay access code 8601697. A webcast of the call will be available <U>here
</U>for 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
IMUNON</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON
is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body&rsquo;s natural
mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach
from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas<SUP>&reg;</SUP>,
is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising.
The second modality, PlaCCine<SUP>&reg;</SUP>, is developed for the coding of viral antigens that can elicit a strong immunological response.
This technology may represent a promising platform for the development of vaccines in infectious diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer
currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting
molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is entering a first-in-human study
of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of
plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>IMUNON
wishes to inform readers that forward-looking statements in this news release are made pursuant to the &ldquo;safe harbor&rdquo; provisions
of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical
trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks
detailed from time to time in IMUNON&rsquo;s filings with the Securities and Exchange Commission. IMUNON assumes no obligation to update
or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMUNON</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LHA
    Investor Relations</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    W. Church</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kim
    Sutton Golodetz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President, CFO </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212-838-3777</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    Corporate Secretary</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Kgolodetz@lhai.com</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">609-482-2455</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jchurch@imunon.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">(Tables to Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMUNON,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Consolidated Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
thousands except per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-bottom: 1.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensing
revenue</B></FONT></P></TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">500</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.743</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,688</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,030</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,422</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(21,030</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(24,922</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain from change in valuation of earnout milestone liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Impairment of goodwill and in-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,366</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense, investment income and other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,575</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(329</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other (loss) income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(396</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">235</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(12,543</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss before income tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,795</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,465</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,280</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,567</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(19,515</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(35,898</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net loss per common share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(2.16</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(5.03</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted average shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,045</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,143</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMUNON,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selected
Balance Sheet Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in
thousands)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2022</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">5,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">11,493</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Investment securities and interest receivable on investment securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,384</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Money market investments, restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Advances, deposits on clinical programs and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,545</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,403</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 30pt; font-weight: bold; text-align: left">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">18,241</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">36,780</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Property and equipment</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">752</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">548</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Restricted cash invested in money market account</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Operating lease right-of-use assets, deposits, and other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,645</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">581</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; font-weight: bold; text-align: left">Total other assets</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,925</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,648</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
assets</B></FONT></P></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">21,918</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">43,976</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIABILITIES
AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,381</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Note payable &ndash; current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Operating lease liability &ndash; current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">231</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; font-weight: bold; text-align: left">Total current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,391</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,037</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Notes payable &ndash; noncurrent portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Operating lease liability &ndash; noncurrent portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,530</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,648</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Accumulated other comprehensive gain (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(388,183</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(368,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,413</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Less: Treasury stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(85</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(85</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,388</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,328</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
liabilities and stockholders&rsquo; equity </B></FONT></P></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">21,918</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">43,976</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !. /H# 2(  A$! Q$!_\0
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MJ\ _&'P_J>H6S_#[Q7HWB"XELHUMYKS28+J)-8T2(Q['D6\M/,B=]VWRP\3
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M>I*<G)1M]KR=DTVU[R/SA_9R_P"#C3P7\8/VAO!/P@\9_ _6/ OA'X@^/I?
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MR/X>>O+2A?WJ<9*SZRO=JVRTT^_JK:E0E&$DW34TG?EDY)/LKQ:?XZGR_8_
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MO_$&8+CSMH47$]@)=R@[U ^;!.:YC_@YT\>7FK_M8?#30!+*MM\.?A'?1VD
M8F)K_6;J34);MHN@:-HXAD9*XQ_"*]'%*6>>.&10Q%2]+A7ARKB,1*>O)5PF
M$]K-RB[)OVDFY**4DW[JVOMSPS'/L).G:*I9=4JQC)I)25.3BHR:N_BM;>*;
MBNE_WC_X-[OAN?!'_!._P;JMQ;E+_P :>,O&>MS32*\4UU9?VS-'ILTJNH8%
MK==T9Y0Q8D4LI&/W#EE"2!7+^6L+N\F"1QMPI.&'">8Y4D$!'<C"EC\._P#!
M-_PMI_@_]A;]F#1M-CCD6Y^#WA35Y[BW*QI+>ZYI<=]=2A00&D::9E9\$J
M:]Z^._Q'T'X1?!7XI?$GQ/J4&B^'_!?@'Q#JUWJUS*!'!<0:?/!9#?E3O:ZG
MCA0 YWO@'H#_ #9Q;5J9]Q?CJD*LZM3&9_4P_+3IRE4J*>,5&E%72]R$81>Z
M?(VTKKW?CL9.57,IT.23<JZC&45[JY9I.*T>J]ZU[-VOT;/X!_CP\G[5?_!9
M#6M&W-J,OB#]IS3O"&EP,6=);+P9JMM=11N(P6*K]F(@4 AAD@G#$?U,_P#!
M?KX@M\-?^";WB_PZCB)?'NL>$?A]<IPBBSEB$DR(!@OC[)L  ^4DJ<J *_F@
M_P"",?AK6/VB/^"J7ACX@74*7<GAG6_%WQ;UMRJR(IEU"]M(K@2,I$CA9;0#
MD,%DW$D#!_6O_@Z*^(<D'P[_ &<OA1'<,A\0>(M:\:W5D)"IEC\/SV]O'))'
MDAEA,SKN((QN)ZG/]$<08"AC/$WPMX:]JI4LHR6EB<3"ER5%3K4L(VXN&L(S
MA[.%1*6[5]XQ:^IQ-.GC,[RW":JE&G]A)M.G3WMK&\E%)WTUT=SX,_X)??L"
M67[6G_!._P#;7*Z5:W/CC6]1TG5OA1XBGMXWNM(\1^ +!YWL8!&&;;JBV_V(
MA1EVFVX$A7/B7_!$K]L35OV//VS!\-/'%U>Z9X"^+VLR_#_X@V&JG[$/"_BZ
MRN[BPT"]NX[SR7M8S)"P+7'E,8I<\C.?Z9/^"!7P[?X??\$[/"5]>P>7?^,_
M&7BWQ3<NB -<6TTZFR0OT$>Q T)Y5F( SN%?SM_\%]OV,'_9V_:JT?\ :%\"
M:>UK\/\ XYZI_P )09],,MK:>%OB=IY62\O+V2,)%$FK726]W91954DAE"CY
MR#R99Q##B7/^,_#K.,0\51S2O7643Q,DO9XC!0G@XQA!^Y%N4XU(12YN>,VH
MZR9KAL>\RJX[)\14?+[6,*$;II1A&4.7WM(V:C*]O1W2M^EO_!T!\3?LOPD_
M9Q^$\=TL]GXR\1>)_%%S!;%&:=/#=K:Q:9/\K-F&9;R<QO\ =D,<C(2%(&9^
MQ5J6K_LL?\$"_CM\2=)M);3Q3XVT'XE:GX:D@<V=Q-J7B2W&G6!%Q* $C,;S
M>7(N\R?=0$U^"O[?W[;,G[;GA+]DO3M2DOU\8?!GX7W/A3Q;K5T!LU/Q%<2/
M8/=J02=LD0@=2<&:<H!R17]27QN^!VN:-_P0/M?A]I%M_P 37PO\"-*\1:S'
MMV2W26\?VW4Y/E4'<8)MV<9('7C-89UEU7AOA?@;@K'QA3Q,N)\3/')R:I5*
M57-(5L*YMN,7#DA2:O%MJ2C*Z3MCB<NK972H8"HZ<:>(Q,)3FO*?M(M)N,?>
MY(\R=^66R<7K^(O_  ;Q?LZZ3\:/VPM=^+/BZRAUR#X.^'9O$+0R*)K6V\6^
M+9&DL;J*YC/E3BUEMKEA, 0SOG (VU_>8MNGS$MM:>'R2T1!<@K@9) X5@^,
M#;G:3MW5_$?_ ,&RWQ>\,^$OV@?C%\)]1OK73+SXC>%]#N_#-I//$C7\_AQ)
MC<6D(=E9Y<7)+8W CY< KS_;Q;X78F "%888;ONE6;)Y  8E>">0H^GY_P"-
MWM\OX^JY=*K&.#HY1A88)TY5J]"57V&'E--3C.E3G[227+2Y4Y)1ZZ^9Q14G
M/&4Z2YI484::Y4N6,4E:3BE[MG):M/F47>6MD4)?(4M;O+'*)84@MH>LTKI@
M.5(&2P"AB55S&?G' P?XO_\ @YSM=#7XO? ;4X5MCXMG^'6HVVH 21S7#:5<
MW=ZEC(NQFD"O*CM"Y0K,T+>4S,&%?V4^(->T;PYI&L>(==O[#0]$T+3[G6-5
MUJ_GBM[+3;"P1Y[^[N+F;$-O;K:Q2.\K. O)X( K_.L_X*-?M%7W_!2G_@H7
M"GPTLY-6\+QZGI7P3^#-I#&7SH^GZNUOJ&M2QKN(:YU![RX5SO$=O(C*?*<5
MV^ N&Q:XS_UK:JU,ERW(LSH9BJ-",<&JM7"U5"56I5A&:DE"<G&+4HQA>*4G
M&3CAS"MUI3E3]E0@GS3UYI62;@U+1<UG)K7IJK)/]_?"GQ6O?A/_ ,&VMMXJ
MUV:>]-[\';KP3#-(##<SVGC'Q%-X9M/)1SNDF:>Z2.- &W@,%W')'Y;?\$//
MV*O#O[5W@+]M#P-\0]"L]3M]:^&6G^%/"&O7D&9-$\6/YZ6NJV,KA8EO;0B,
ME4<E4W%]O%?HO_P6QT2U_9>_X)/?LZ?LMJ6,'B#7_"^@WWV0"%9I_!>GR^(W
MC6)<']YJURI>,##K'YC$&.O:?^#:KP%-X=_8Y\?^,+LM<:CXU^*>IW5A=&+9
M/!9QVZ6Z1-N&Z2*VN Y52<$+D8+5]+#,YY-X?\5Y]@*\L)5SGBK&2PE7#N5-
MTZ5+,(.#C5BXS]^G"=.IJU["4K*\I)^DZWU'+,=C:4W">(QDH4U!<L5%5TM-
M&Y7491D[I*,G;LOYRO\ @G5^T'XT_P"";O[?5OH'CN6^LK33O%LGP/\ C+H>
MHE[*"_TJTU!_#FAZS+$R*L+6I@MM2MGG"M-Y\K E-I/])G_!QK\4K6T_X)_>
M%O"&FWR?9?CU\4_">EVDD;H8-;LM%@7Q5:Q*Q($K7<%EYT21EC+';NX!$>X?
MFO\ \'(_[%3>#/B?X3_;!\&:! GA7Q_(="^+%OI\36[Q^+]/*?V=XJOYX=NV
M&>S@L+B%D82#4!=R2,6G&/RG_:Q_;ROOVG?V,_V4O@-XCN-6N_%W[/UUKUQ<
M:[?SO(NNV,VD#3M.O7RQ9KJQL)/L< /[T([Y;K7TV7Y'A>.<P\.^,\JI4ZF(
MP$)3XA2M*+J8:E7?-5;3ESPKJREI)QFO><8QY>VA@Z>,JY=F<8Q<?:6KO=MQ
MI2DU+3EM&:?O::I/?0_I1_X-G?AV-#_9B^*GQ EM3#-XT^)0ET^X21GA?2H+
M54$<,@RDB&7YB5+#[IZC!_IGW <;,8[;5X]OOBOR'_X(B?#@_#7_ ()R? BR
MDMQ#?ZY97^N:B6^61WN-2F%LC,/O[+8(JOT8*#U(Q^O1VY/RL?<9P?<<U^ \
M?5J.<\<<38NO%5FLP="',Y.,8X=.C:$KW<6XW5V[6\SX[/,3)YKC%247%5+)
MR;O:*Y>\5OK?KV1<HHHKY8X0IC1H^"PR1QU(XR#C@C/(!&>AZ4^B@"N8SSL(
M503A<?7..O!)R/0@8QBL^[601.(H]\@)P4^4@##$88XZL-H&#E<D\ 5KD9&,
MD>XJF[%2Y& H<C&,GH.GH"?K@8P.,&)[;-M)M6=GT32;T3:T3L["UYH[6YE?
MSUV[Z['\L7_!SC\3)-!^ _P*^&J7"P_\)QXZU^[UBR!;RWTK2[<S13,JDL I
MD'E@J07!*C &?IO_ (-S?AM#X)_X)_0>)TMS:K\4?B=KGB^.50ZR70^S6&CP
MM+E0PA;[ 4)!9=CG<V-XK]=OCC^RE\ OVB1IDGQG^'.B>/I-$CD_LM]:B\TV
M7GHPF-NH^6,NJL& X;=V' ]!^%OPJ\#?"'P;I/@#X;:#9>%?!N@VLUGH^@:=
M$L5C8K<$S.T2@$[GWMN8DX8DA3DU]Q/BRC5X'I<(TJ$Z<?KU+&U:S;?M53E-
MN%T^;2<HV;N[0U>J:]IXRC++UA:?-&HJD)7LVK;R2;=WO9.2NHI[N2M_GR?M
M_P#B)/V@?^"OWB?PY'=?VAI?B;X_?#+P#I1M5::);>+4K#2]6@RY;"I)$1,4
M4@IN'4FO]#CP_HR:'X=T'0(92D/A_0],\/PW$* E#I]A#9KMCV+^[6*-=I 5
MD).,$-GY9LO^"?O[(UA\1(?BA;_!7PG_ ,)Y;^)1XL@\126[27T/B-+@WBZI
M'(P)$ZW.9@QS\^, 5]E6]N8E6,7$KMS*[ND8,C2'>Q8* HR'"X51@#@]SS<7
M\6+B"ADN%I8?V%'*\!A\#"%HVYL/1I4)5;Q:;E-0;>TI.7,Y72(S7&4<7#"Q
M@I)T*<$[IQ5XQ48M6=FM'H]=5>[6OD_AKX1?#3PIX_\ ''Q*\/\ @C0-+^(/
MQ!^PR^-?%EO90'5-?M]-BAL[:SN;XQBY:S2.%76V8JBL<E6(4K^,G_!Q3\1;
M/P;^P)J'@NYN(D_X6KXQT#0#;G]U+=+8SKJ"1!8L;8M\:*X"E>@VX.:_?&*T
MB#R,N5\U9,KG<H+N'+9(SG<<X^[@#BO#OCC^S;\%?VC-)TW1OC1X&TSQUI6B
M7YU?2;+5@TL%E?[?+2XC3(&] <C.1GKD=?#RO.%E>?Y'F>(A/%O!8NFX.<N;
MDA2B_8PA"?,DH*Z@DTHI6LKW?-AZ_+6A*7O.D^6"G%3T7*E'EE>/NMW3>^FC
M1_.__P &Q'@1](^ G[0_Q&OK?=<^*_BEX?T/39C (XETK2]!FGD6',:NMN;N
M4$X;(D'0$UY]_P '('[%_CWQKJOPO_:N^''A74O%^D^#])U3PQ\4-"T"%;B\
MD2XGAETO5KZ QKOTVQC9VNW,A<%<E-BMC^GCX.?!#X:_!#PP_A/X4>%M+\%>
M&3-->R:/I-O'%;27D@!-TX*,QE1=J+\V"N0>BUZ3J^A:;JUI<V&J6EM?V.H1
M&TO[*[MH+JTN[20;9K6:WG1XI(Y5?#,ZER!MZ&OK<1XB5LO\1L?QY2BWA<=+
MV57+JD5*$J,Z5*G4HS3O&THQYTDG%R:YKIM+OCC_ &69+%)WC2BH-17(E2Y%
M&5-):*ZYKRLWJGOM_ K^PI_P7?\ CM^QS\*M"^!GB[PSHOQG^'7A>UE/A37_
M !#>ZA;>.M*MK@L__"/HEM=1VEQI6ERNMK:*8R\,2>6&0G:WF?[<7_!7;]K7
M_@HKI%C\#],\+Q^$O &O:G$@^'OPR&LWFM>,&4J;6U\5/J$C12V*W?E-]EM9
M65F9CY0Q7]BGQ(_X(\_\$[OBEJ\FM^*OV>/#J:C-='4-^B75]HL$<_S,XAM]
M/F@BAC?+,T2#RM[%MF0I'L'P&_X)T?L<_LT7DVJ?"#X)^%_#VL3D.-8NX#K>
MI0E7:0FWNM5-Q);LI4['B(;D GC-?:4_$SPSHSCFN7\$RIYY*4JZQ<\35G3^
MM5.9^TA0J\V'I+F;:Y*;Y;6BU:-_1_MK*N:<U@E[:;OS.[ESM[J5ERMJR<EK
M)*S:5[_FQ_P0P_X)OZ[^QY\)]>^,?Q;L2OQT^,44%S<Z?<QQBY\(^#PJOIWA
M_P L01O:3S$^=?P1NZEHT.XN*_$/_@Y1^)"^(_VV? 7PO@GDNKGP%\.] TUK
M.(233VT7Q";RY'A<$CS3,R.#(%955<!F&*_NU,"Q&7R]JLQ4,VWDJ0H48X&0
M0!G^[QV%?)'Q0_89_96^,OCL_%7XE_!SPMXM^(-U%ID$OB75+=I;Z2'12)=,
MCE)RKBS8@Q9!^ZH/'%?$Y-Q]B,'QM/BG%4Y5L1B88CDM&-2%!U(\T84J51VY
M(4E:,5*,%=RMS-Q/*P>=>RS1XJ-/WU2<:?-:4:;<FFI1E=2]V^^B;OO:V+^P
M+\/8OAC^QI^SCX,A26WFTCX6>'TNO/7B6ZDM1<7$]PK(&DN6FDC<9 #*I5\X
MP>)_X*7_ +(NB_MG?LH?$?X2W5L)/%5CI5UXL^'=RCI;O:^+M&MC/IBMLAE=
MH9C'+%+!$ SO)'MY4@_>5AI5GI%CINCZ;$EIIEE:6]M86<2*L-K#!&(HT0 9
M  PVS) VA00#D:4EF&D:1B"ZJH0X!VD$D'E<$84Y!&#G;CO7R4LYQ%'.:O$=
M"<XXB.;SS&%2+Y:D'.K*I:5M90?-9TV^5Q]UJR1XU+,)T\UK8F$7&7M?:MJ5
MM9.4I/E3MJGIV5E;<_RBO _PWUS6OC/X/^#6L6LVG^*+_P"+&A>#?$FB_9I$
MNX=4TW7-/CDB;9"Y6)TL;BYDZ!H9!D%L@?ZEZ> _#=]\+;/X?ZOI]G<>%KSP
M/:^%M:T>XMHKBUGT2ZT:+2[VUDMW1@T921I%!1E\T*[J0I%>&R_L#_LC-\3V
M^,0^"7A%?B-<>(!XED\2I9B.Y?7U#(=2,:?N4F_>LV54Y8DD#BOKN6)2HB.0
MKHL:E,(VU3@;B!\HZ949# 8XSQ]OXA>(E3CN625J=*>&K9;"G.I./)3<Z]J+
M=9>S234:E+G@I7Y;NRUL>QF^<2QJHS;G:$DO>=W&45H]];-:/=:I;L_SE_V[
M_P!AO]H3_@E]^U!<?$'X7-XST+P/8>,M3\5_ ?XR>&8EN+SPKILUTUXVB:Y)
M&L5BL=RPDM7AOB8X[4PA#G@_H;\)O^#FGXV>&_#5KH'Q-^#'@?QGXATG2(XU
M\3VVJ:M:WNN7J0;7O-;B2ZBL;>6Y<>9.FG?NAN"Q[L$+_9=XV^'7@GXDZ1?^
M&_B!X8T3QEX?U"-(KO2/$&G6NH63Q[6!VP3Q.H9E;!;(8%5(;(S7YO>+O^"*
MW_!-CQIK?]N:Q^SKH\5^L\ES(NEZIJFFV<CO\SHUK:W4<)CR/E38H XZ 8][
M!>*?!V:9='+^..%Z>?8S"24/[1A*6&Q,JL(*"FZ^'<*]I)TDZ;G*FI1YHQBV
MW'M><X:KAJ5'%8:-5PI17M+6;OS>]S1]])MK2^K2NM%;^/O]K7_@K)^VS_P4
M9D@^#^D6E[X+^'/B.X;26^$GP*M=:U+4_%\U]<QVT6F^)M0V2:@=-E64B>,L
MMN$E9B&B#,?W?_X(L?\ !';6?V>8K+]J7]IWPY:V_P 9K[3]_P /OAO<R6US
M:?#R*Y"'^UKB**%H8M4O(/+:*(S/<VQ+F=48[:_<OX$?L0?LK_LWV[_\*7^#
M?A'P==IYCC5X=.ANM<#",(675KL37B'8,+LD 7 (P>1]/Q@!8PQ+LS#<^ KL
M.#'O*X#M"C(JN<%L-OR>3XG$WB7',<CK9!P!@J/"F48J25>E2I4ZM>O*"Y)+
MVTU&LJ/)SJK"56;KW:FVI2(QV<4JM*G0PM!4*<&G)02A)V2=G*+3DVU:3E>Z
M;3;;;/XV?^#H#XE_;O'_ .S1\'O[0%M)X<TKQ!X\DLK3?/<&Z\00Q:%;7\\9
M+JL:7+.8N-ZI&0A!917[P?\ !%[X>I\._P#@G9\ 8& -_K^A7/B#599H56:X
MO[F\G_>291)-TJHK@N-X0XW#DU]9_&;]BG]F3X_^,+3QS\7_ (4Z!XV\56&D
M0Z-::SJD;/=0:5;2230V,?.P11S,9DXW"15YQ7O_ (7\&^'/ OA_0_"/A32[
M;0O#>AVJ6.DZ38QJEK90QKA%B4C@*>1DG)))!/%>9F/%F#QO!F2<(X/#U,.\
MMJ5<1F6(J/VJQN,JJ;J5(\WO4H.33C1C>G%KW7L>77S.=7"4\):/L:4^=>[=
MJ<KJ3;>KNVFD[J+V/G[]L+]G/PO^U=^SQ\2O@;XOTZ"[L_&'AV^M[*>1(B]A
MKUK$;C1YHI&1UB,=ZD9E,85GARN2[8K_ #%/B7\)/&'PJ^*OB/X&>*='FM_B
M)HOC>3PJENUI.(9+1M1M-/A6U"# %Y %EB.P*$RS;37^L:+90"K.TN6#/O"@
MO(6"JY*CJI0  # 4D\L1CY&\<?L(?LH_$?Q])\4?&7P<\*ZSX\N=2L]4G\0S
M6:B[>]LK=X[><E H9P0)7+#+2JA)(!4^CX:>)-?@3#X_+FIXG"9A"K3C3E"%
M64*SC*\Z;FTZ4)T[<U.+44TFE96._+,ZE@:4Z33G3J0LHM*5I:7E>6WNJUHZ
M?>SNOV6O!<?P]_9T^"G@Z&VCM#H7PT\'6\\$:[4^VMHMB]X2I4,'-P92Q*C<
MY+'+8:OH8B,DD@Y/)X7O6?9Z?!I\%I;6:^1:65K;P0VZ8V)# JK'&HV\*B;5
M7G/%7_.3^Y_*OSEX]XS&YCBYW2Q&,K5(O7F?-4J2ES:[WDM7KH>#B_:8BO.M
53NG.4I2N]/>ES*UU*UM4^[]$C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>imnn-20240328.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6PGbP9z5Z8aekhvWB4bfnqbyclwrKY+SZyWVh2IcAB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:IMNN="http://imunon.com/20240328" elementFormDefault="qualified" targetNamespace="http://imunon.com/20240328">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://imunon.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imnn-20240328_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imnn-20240328_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>imnn-20240328_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>imnn-20240328_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imunon.com/role/Cover" xlink:href="imnn-20240328.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imunon.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140674025327728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 28,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Imunon,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000749647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-1256615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">997
    Lenox Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lawrenceville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08648-2311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">896-9100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value
    $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMNN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/;"=YC+@6Q%%: ;+ED!Q3W\/6-3B3*NM@%M54N*:T]\QM+)+4-S<WZ/-5&K
M;/X6R>D7!%?TNNUFM^%?H=9,RUY!<://!W,$<]G3/+C I[;7^XRAE&V"XO[^
MH )(S6RC)-:W:D2ZO7:C5U/Y98>@N+%_T\(8+B$U,?2>HP^GE52X4-VL@Y;=
M@>)F/E>1"(01<DT>H<JU8%$E#ZY2Q^.7W<#'_7JF>2. ]-@W^C YA/D93&._
MKE;5XU>C5TM6M@ ?]^O_D4W2- .R6D!<MA;PS70?=^F%,#!#4RM"_4_+SV3.
M@PSJK7+^4:-DZQ,F"+!0"IXO2,(TV;(HXWF[^LF[]"A)X(G3#=,H>=D1?-S"
M%YJ%M@+G+_%25=9?C<#D<3K%2$KK]W&;?DT:N=L'&R;7_.3<LD9H.IK?CO[
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( *= ?%BJQ"(6,P$  "("   /
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ IT!\6+4_(Z1?!   )!$  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *= ?%B?H!OPL0(  .(,   -
M              "  :,,  !X;"]S='EL97,N>&UL4$L! A0#%     @ IT!\
M6)>*NQS     $P(   L              ( !?P\  %]R96QS+RYR96QS4$L!
M A0#%     @ IT!\6*K$(A8S 0  (@(   \              ( !:!   'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *= ?%@D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( *= ?%AED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imunon.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>imnn-20240328.xsd</File>
    <File>imnn-20240328_lab.xml</File>
    <File>imnn-20240328_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "IMNN",
   "nsuri": "http://imunon.com/20240328",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "imnn-20240328.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imnn-20240328_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imnn-20240328_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://imunon.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-24-011614-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-011614-xbrl.zip
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MG3>/;[:!Z;G#1-C"@2EBM[PDMPU36FC[(.8 V\?S)X66)V%6O:+KI6Q(,(Z
MS,TN(CW2!HG\U",.J("H? OOLI5 I)AJ-B4SDU!)>9)I8"B?2VU;6A*)!]G#
MK1S)IYQ0'8A*@7L1BN%;M39@B'8<,6:3\D%9H .7A3^B9Y*\B6$I)XB!T(#X
MM!J#6.]*?2H=6^>(%G*[K.-](OH6<G(N*ULC^3^A3%)"D8& ;HHA >(0Q(51
M;85SYG,Z2$#T"MN#%R7Z"_%H4^<@]OU8O75(NL38E9@1\2ZO"T>W_3!1?L;C
M 01V'T&6Z%'X>#['OA"9,!&,9FA(M+J_IN$,VFK/Z2)L5:@#[_:6GZ;P!?R7
M#5L0"O7,6P7SD9UK;+0I5SN?"R.SS8X8.!'\P[.)K\M.X'2E.JSL#_#7.*!3
MUGZV9??C,7E3* Y#6P"!1^P9$"U1;UE&9>5R)LY"E*#2D65 _# ;@E$NF.5G
M[FZ8VD+;_Q58A<<YVHB#RI.&*(EX*X!V $'HG<R9 'E0QQJ*X\\7K(03(B8&
M(ADZ#D4 2/=AGUO*%L:4;@=8 !'BP'']"#6]K&?1,@>,O3H7/).#SIM,4]"3
M]/-P"$OW0S9+0O([.G@F0%!@.7=@ +F@NPA,_Z=(''"BQ)8D=D2*59*B3L_X
M?6;O;>!I'MR2!/%O\PJNV0X5[Z- HX<>4+@UI<)APDWL8?X[*H%I/A):HI+Y
MO0I :A6/ Y'PE"T'6,2 ;DZ@8_:;XCO!V+1ZF K9EG;HV!.&#+(I#XC.':NP
M2&@-N2PL- )=-'MQDQ9Q!!!DJ,").&13'(.1Y G(Y[H^[!5W'47D]X4-9;P#
MVM"ZZSF8)P'BI^_\2Z)/'<:BX@K .=N'QU!_0E9[ERIS;3]13#4FCE< (#ZZ
M&Z[Q\O;9GR#G&'' F$=MOXV2$*_K&^C(*/QEP4*%%S$ 5@*B\%'XPW4#D9.5
MCZX)%ONIN4ZA.5:DB%HB_0JPSN5HC8MRY2#C&")UHC2&;\ 7K)ZAL! D,R6U
M)2)[TN<%ZK[OVJ2=]Q$U >\S\@I80!^(D\2NZ_O?<(-W*$;9SX'RELPC="Z0
M>L]'IW.P]\RWON$"2!F(T!T_34],]'OTHVGW&;Z6BB/66-N_K_KU_DA"?1-)
MV$02UBV2\ +%WD]#M%>GQZ?G-_G<R>G7T[.+R\_PC^MU/]/KN)F#+X?:P93/
MM;+NQX.=+\OMF["YH\5/<5]9W5$FF;(UZ1 ^40[A*65331V\NE :S[$*7B&D
M1IS.[ 2/TO)F!4>QO&LRT[3K66[MB>@;5AV/G0L5/ETW@/&B3 T&Z?H^.EX,
M%3<R.'_$M(:T3MO1WAYVDS@862)+$JP0-+)0Q80_WEO,@>[5D<(,3]Z!W6H[
M)BA?8>(AUJ"7 _@GF!QH^? M&*# NECD#A<2Q:!X8J$SN;'  LWL0D<:><$0
MS!ATE[")%?; R/W&#NZXC^80NJ)CJX<_!WX8.IC]2DKD("(3,8P#/CFHJ3Z6
M[IF=B'SA6.IG#2U7<KUMUI>,:74ZG(>[,-)#QUA2TO4Y0G%+Q>?MV/U&)AVL
M!,:TD7KRVT.UCFG;CLKLXR7%V(JD")/.3D9V $>V8\RCPT.NKSZ[YB;;#99R
M^F"$%URS+=V4^&PGX,QCQ"?/3E&4:< 3^Q0W\CH.F^\)MA *^W<39935G\9C
M., CT!B3GHH_ 8:QRVDTL$-1#_'?">EN3XU2J<?0<;W-EB-'O$URMML#WV$G
M"Q>77\#*:6PZ<0^CP\)@)\^$[]C(TEG&G1S*@!]./L[ZJU5R0.+ 3YF;]JH
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MI8HEIZ4 ])K%MC*#PM^05%X;+]FQ3I_+YU1-1\B*6XBH@"G;E ,YV^,T:<B
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M'@!'5F-&BYU<%UOO=U/#82241<F&W %ZJLNU&17@X\)G[,8<B5-0JT';U@X
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MN8]<H4E- <QMS.ZME2N%:GFO4*^5JV)KI*1S![^WK7*<PF])*CJG///13LT
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M+@;HQP/M_\P,HTWO]"?H,[Y*0G4".W:.+D[^.L1??KOY?';X_P%02P,$%
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MVJN$I31=&PUPENF,B(4A*DC'#:SG3)_(G8H?X9) NV"](ZG7Y%IX0]5#.WZ
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M4Z^!EI"S(2=&NN%J]Q *5"@K+Z[ 8RHDI/X*/I %81E\Z&;.%2C>"#W*H-A
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ML'M,03GXIA%HNYF:.OX&4$L#!!0    ( *A ?%C]' +[_0H  ("&   5
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M+FAT;5!+ 0(4 Q0    ( *A ?%@" V1*0!,  %NB   +              "
M :HP  !F;W)M."UK+FAT;5!+ 0(4 Q0    ( *A ?%AZ]T0'*P,  -T+   1
M              "  1-$  !I;6YN+3(P,C0P,S(X+GAS9%!+ 0(4 Q0    (
M *A ?%C]' +[_0H  ("&   5              "  6U'  !I;6YN+3(P,C0P
M,S(X7VQA8BYX;6Q02P$"% ,4    " "H0'Q8'</'TU8'  #15P  %0
M        @ &=4@  :6UN;BTR,#(T,#,R.%]P<F4N>&UL4$L%!@     %  4
*-@$  "9:      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imnn-20240328.xsd" xlink:type="simple"/>
    <context id="AsOf2024-03-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-03-28" id="ixv-401">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-03-28" id="ixv-402">0000749647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-03-28" id="ixv-422">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-03-28" id="ixv-423">2024-03-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-03-28" id="ixv-424">Imunon, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-03-28" id="ixv-425">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-03-28" id="ixv-426">001-15911</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-03-28" id="ixv-427">52-1256615</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-03-28" id="ixv-428">997     Lenox Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-03-28" id="ixv-429">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-03-28" id="ixv-430">Lawrenceville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-03-28" id="ixv-431">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-03-28" id="ixv-432">08648-2311</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-03-28" id="ixv-433">(609)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-03-28" id="ixv-434">896-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-03-28" id="ixv-435">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-03-28" id="ixv-436">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-03-28" id="ixv-437">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-03-28" id="ixv-438">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-03-28" id="ixv-439">Common stock, par value     $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-03-28" id="ixv-440">IMNN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-03-28" id="ixv-441">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-03-28" id="ixv-442">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
